Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...
Cancer
SEED Therapeutics Completes $30 Million Series A-3 Financing
KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational...
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd....
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - September...
AI in Oncology For Analytical Solutions Market Size & Share to Surpass $8.86 Billion by 2035, Growing at a CAGR 21% | Vantage Market Research
Global AI in Oncology For Analytical Solutions Market to Transform Cancer Care Accelerating Early Detection, Precision Treatment, and Patient Outcomes....
Genomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and Japan
Mastermind® FLEX Data powers Compass Bioinformatics's InheriNext® platform, bringing unparalleled genomic evidence to leading institutes across US, Japan, and beyond...
Hemogenyx Pharmaceuticals PLC Signs Letter of Intent
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in EstoniaFirst Potential Near-Term...
Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board
VANCOUVER, BC / ACCESS Newswire / September 22, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")...
The Digital Medicine Society Unveils Healthcare 2030 — A Blueprint to Transform U.S. Healthcare in the Digital Era
Launch coincides with the Healthcare 2030 Summit in Washington, DC, bringing together top government officials, industry leaders, and patient advocates...
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion...
Thynk Health Appoints Matt Rockhold as Chief Commercial Officer to Accelerate AI-Driven Cancer Detection Across U.S. Health Systems
LEXINGTON, Ky., Sept. 22, 2025 /PRNewswire/ -- Thynk Health, a leading innovator in AI-powered diagnostic platforms, today announced the appointment...
Medical Care Technologies Inc. Introduces AI Breakthrough for Squamous Cell Carcinoma Detection
MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant...
Medical Care Technologies Inc. Introduces AI Breakthrough for Squamous Cell Carcinoma Detection
MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant...
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of...
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challengesSEATTLE and VANCOUVER,...
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based...
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key...
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian...
Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
CHICAGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global...